The activity and abundance of >160,000 variants are quantify the activity and abundance of >160,000 variants to construct complete maps of the energetic and allosteric architectures of five human kinase domains: SRC, FGR, JNK2/MAPK9, ZAK/MAP3K20, and TSSK2.
Abstract
Protein kinases are central to biological regulation, dysregulated in many diseases, and the targets of a hundred clinically-approved drugs. Structural conservation of kinase active sites makes the development of specific inhibitors challenging. Targeting functional secondary sites can increase specificity, reduce toxicity, overcome resistance mutations, and also activate kinases. However, the functional secondary sites to target in most kinases are unknown, and the conservation of allosteric networks in kinases and other proteins that share the same structural fold is unclear. Here, we quantify the activity and abundance of >160,000 variants to construct complete maps of the energetic and allosteric architectures of five human kinase domains: SRC, FGR, JNK2/MAPK9, ZAK/MAP3K20, and TSSK2. For inhibition, all five kinases have distance-dependent but anisotropic allostery and each kinase has a unique allosteric architecture, surface, and set of pockets to therapeutically target. A set of functional secondary sites is conserved in all five proteins, but other allosteric pockets are protein-specific or switch from inhibitory to activating in different proteins. The differences in the energetic architectures are particularly striking for activation, where the allosteric maps are highly diverged. The allosteric architecture of each kinase is therefore unique, with a distinct set of functional secondary sites to regulate and therapeutically target.
The structural and medicinal chemistry principles underlying (i) allosteric inhibition and (ii) proximity-induced degradation are summarized, with an emphasis on design logic, structure-activity relationships, and key liabilities in the beyond rule of five space.
Mei Zhou, Linshan Li, Xiao-Juan Tang et al.· Future Medicinal Chemistry· 0 citations
Dynamical network analysis is used to identify key residues involved in a dynamic allostery between the N- and C-lobes that connects the major functional units of the MAP kinase p38α, providing mechanistic insight into p38α allostery and suggesting viable opportunities for the rational design of allosteric modulators o...
Suchandra Roy Acharyya, J. Weisner, Rafael C. Bernardi et al.· Nature Communications· 0 citations
This study utilizes a chemical genetic approach to sensitize LRRK2 to existing GTPase inhibitors and shows that pharmacologically engaging the Roc-COR GTPase domain in cells decreases but does not fully inhibit LRRK2-mediated Rab10 T73 phosphorylation.
Rachel E. Prorok, Lawrence Y. Zhu, Vickie Bowcut et al.· bioRxiv· 0 citations
A machine learning-guided structural atlas of 11,945 kinase-inhibitor complexes is constructed and it is demonstrated that evolutionary proximity is a statistically significant predictor of shared allosteric pocket accessibility, making drug discovery more efficient.
Rudrakshi Chauhan, Rajiah Aldrin Denny, N. Murugan· bioRxiv· 0 citations
This study maps the landscape of GPCR classification and function by translating the majority of the GPCR structures into structure graphs and analyzing over 2 million structural contacts to capture key aspects of the structural communication within the GPCR superfamily with implications in drug discovery.
Sara Gentile, Angelo Felline, Sara Mazzali et al.· JACS Au· 0 citations
Together, these examples define an expanding pharmacological vocabulary for kinase drug discovery: one that asks not only whether a molecule inhibits its target kinase, but how ligand binding rewires protein stability, interactions, localisation, and function.
J. Diepeveen, Z. Kozicka· Chimia (Basel)· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.